Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible,anti-aquaporin 4 antibodies,B cells,Th1 cells,Th2 cells,Th17 cells,or others?
Restricted accessResearch articleFirst published online August, 2017
Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible,anti-aquaporin 4 antibodies,B cells,Th1 cells,Th2 cells,Th17 cells,or others?
Some disease-modifying drugs for multiple sclerosis, which mainly act on T cells, are ineffective for neuromyelitis optica spectrum disorder and induce unexpected relapses. These include interferon beta, glatiramer acetate, fingolimod, natalizumab, and alemtuzumab. The cases reported here suggest that dimethyl fumarate, which reduces the number of Th1 and Th17 cells and induces IL-4-producing Th2 cells, is also unsuitable for neuromyelitis optica spectrum disorder, irrespective of anti-aquaporin 4 IgG serostatus. Although oral dimethyl fumarate with manageable adverse effects is easy to initiate in the early course of multiple sclerosis, special attention should be paid for atypical demyelinating cases.
KiraJItoyamaYKikuchiS. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12-months: Results of a phase 2 observational extension. BMC Neurol2014; 14: 21.
2.
YamoutBIBeainiSZeineddineMM. Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder. Mult Scler J2017; 23(9): 1297–1300.
3.
FoxRJMillerDHPhillipsJT. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med2012; 367(12): 1087–1097.
4.
GoldRKapposLArnoldDL. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med2012; 367(12): 1098–1107.
5.
SchillingSGoelzSLinkerR. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol2006; 145(1): 101–107.
6.
LinkerRALeeDHRyanS. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain2011; 134(Pt 3): 678–692.
7.
ScannevinRHChollateSJungMY. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther2012; 341(1): 274–284.
8.
ParodiBRossiSMorandoS. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol2015; 130(2): 279–295.
KinoshitaMNakatsujiYKimuraT. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun2009; 386: 623–627.
11.
BradlMMisuTTakahashiT. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann Neurol2009; 66: 630–643.
12.
Schulze-TopphoffUVarrin-DoyerMPekarekK. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci U S A2016; 113(17): 4777–4782.
13.
GhoreschiKBrückJKellererC. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med2011; 208(11): 2291–2303.
14.
LongbrakeEERamsbottomMJCantoniC. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler2016; 22(8): 1061–1070.
15.
GrossCCSchulte-MecklenbeckAKlinsingS. Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2015; 3(1): e183.
16.
SongZYYamasakiRKawanoY. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod. PLoS ONE2015; 10(4): e0124923.
17.
JanderSTurowskiBKieseierBC. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler J2012; 18: 1650–1652.
